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Bacteriophages are viruses that only infect bacterial cells and can be used to treat antibiotic resistant bacterial infections. This study
focused on the isolation and characterization of bacteriophages lytic to Staphylococcus aureus at Coastal Carolina University (CCU) in
Conway, South Carolina, as a means to isolate bacteriophages that can potentially be used to treat methicillin-resistant Staphylococcus
aureus (MRSA), an antibiotic-resistant S. aureus variant. From 2014 to 2018, collection of ear and nose samples from 225 randomly
selected CCU volunteers was conducted. Filter sterilization, amplification, microbial tests, and PCR analyses were performed in order
to identify and characterize bacteriophages. Coliphage populations were also monitored as an indicator of temporal competition and
fecal contamination. A pilot study was initiated in 2017 in which 15 CCU volunteers were sampled once a month from October 2017
through March 2018 in order to investigate coliphage and S. aureus phage population dynamics. The purpose of this study was to gain
insight into the lytic Staphylococcus aureus phage repository found in the CCU community, and to explore S. aureus phage dynamics
amongst the CCU populace. Results indicated that a considerable S. aureus and E. coli phage reservoir exists amongst the CCU
population. Most phages could not be characterized via PCR analysis, suggesting high diversity. The preliminary study indicated that S.
aureus and E. coli hosts potentially exhibit temporal competition, of which might be explanatory of phage population fluctuations.

Introduction
Bacteriophages are viruses that only infect bacterial cells [1]. Also
known as phages, these viruses are the most abundant semiautonomous
genetic agents in the biosphere, making up between 1030 and 1032
particles on Earth [2]. As the most ubiquitous living entity on the planet,
bacteriophages play a key role in regulating the microbial balance in
every ecosystem previously thus far explored [3]. Primarily killing
bacteria during lytic cycles, bacteriophages lyse their hosts by inserting
their genomic material into the bacterium, hijacking the available host
machinery, and using the bacterium’s apparatus to synthesize new phage
particles. The host cell then lysis and releases new phage particles
capable of destroying bacteria of the same strain. Such high specificity in
host selection has made phage therapy a popular topic of research in
Russia and various Eastern European countries since its co-discovery in
1915 and 1917 by Frederick Twort and Felix d’Herelle, respectively.
This geographical seclusion in phage therapy research and application, in
turn, can mainly be attributed to the discovery of antibiotic “miracle
drugs” such as penicillin in the 1940s, of which became the focal point
of antimicrobial research for a number of decades in most of the Western
world. Analogously, phage therapy has been ignored in much of the
twentieth century by the West due to poor predictability of phage therapy
trial results and outcomes attributable to an alluvion of causes, including
contamination, phage-bacteria specificity, horizontal toxin transfer
amongst temperate phages, antigenicity of the host immune system, and
bacterial coevolution [4].
Nevertheless, hundreds of successful phage therapy preclinical
studies in both animals and humans continued to be conducted in Eastern
Europe and the former Soviet Union. Worldwide phage research became
predominantly centered at the Eliava Institute of Bacteriophage,
Microbiology, and Virology in Tbilisi, Georgia, and the Hirszfeld
Institute of Immunology and Experimental Therapy in Wroclaw, Poland
[2]. Numerous phage therapy trials, such as the famous 1960s Georgian
study illustrating a 3.8-fold decrease in dysentery incidence in 30,769
children administered a cocktail of bacteriophages over a 109-day period
[5], gave rise to a preference of bacteriophage administration to
antibiotic treatment in select Eastern European countries, as is
epitomized by the numerous commercial phage preparations sold in
Russian and Georgian pharmacies and transported to Western European
countries as a “last resort” treatment option [2]. Whilst many scientists in
the Western sphere deemed Eastern European phage studies to be
dubitable in outcome due to limited study control measures, the
monumental amount of benefits attributed to the usage of bacteriophage

therapy, as excavated and delineated by twentieth-century Eastern
European studies, was recently corroborated and ascertained by several
experiments in both the United States and United Kingdom, as reviewed
by J. Alisky, et al. [6]. Phages are the natural products crafted by billions
of years of evolution as highly specialized deliverers of diverse
bactericidal agents targeting bacterial cytoplasmic contents. The benefits
of bacteriophage therapy can thus be framed in terms of the biochemical
properties of the virus [7]. One such benefit of phage therapy
circumscribes bactericidal traits, in which a bacterium infected with an
obligately lytic phage is incapable of regaining viability [8]. Another
benefit of phage therapy is auto-dosing: phages increase in number only
where bacterial hosts are located; therefore, phage numbers are
specifically dependent on bacterial count and host location, which
extemporaneously allows for the propagation of an appropriate number
of viral particles in the system predominantly in infected locations only.
Furthermore, phages, when correctly purified, are deemed inherently non
-toxic for human administration purposes, albeit the release of bacterial
toxins upon lysis remains a possibility, as is the case with cell-wall
disrupting antibiotic compounds. Moreover, these viruses are known to
have minimal disruption of normal flora, a narrower potential for
eliciting resistance, along with an efficacy for biofilm clearance not seen
in conventional antibiotic treatments. Phage particles are also much more
easily discovered, with versatility in application form (e.g., liquids,
creams, solids, etc.) representing a pharmacological benefit in phage
therapy treatment development, as viral particle administration can even
be combined with antibiotic compounds for improved efficacy in
treatment success. Additional advantages for phage therapy include
single-dose potentials, in which phage amplification is a singularly
administered dose serving as a curative agent against a bacterial
infection; phage transfer between subjects, when cross-infection may
spread to other untreated individuals in a community; and phage
administration efficacy, in which a small number of viral particles are
needed for bacterial lysis. The implementation and administration of
phage therapy thus has an immense amount of conspicuous benefits.
Yet, despite its long and successful Eastern European history, phage
therapy remained unauthorized for routine use in human patients in the
West until the late twentieth century, when the rise of antibiotic-resistant
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA)
and multidrug-resistant Pseudomonas aeruginosa (MDRPA) created a
need for phage research and application, as evidenced by the European
Union’s $5.2 million contribution in 2013 to Phagoburn, the first large,
multicentre clinical trial of bacteriophage therapy for human infections
[9]. Such recognition of phage therapeutical significance was reinforced
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the following year by the United States National Institute of Allergy and Escherichia coli, and can these phages be characterized via PCR
Infectious Diseases (NIAID), a center listing phage therapy and phage- analysis?
derived lysins as a vital constituent in its national approach against
In addition to this sporadic study, a long-term pilot investigation
bacterial resistance in its 2014 strategic plan [10,11,12].
into phage population fluctuations was initiated in 2017. Fifteen
This study specifically focuses on Staphylococcus aureus bacterial volunteers from Coastal Carolina University were randomly selected and
hosts and their respective viruses as a means to fight a variant strain of S. sampled once a month from October of 2017 to March of 2018 in order
aureus, methicillin-resistant Staphylococcus aureus (MRSA), an to investigate coliphage and S. aureus phage population dynamics. The
antibiotic-resistant bacterial pathogen once again becoming a prominent purpose of this pilot study was to provide a general understanding of
re-emerging threat to global human health and well-being [13]. The bacteriophage population dynamics over an academic year, as
bacterium, known to kill more Americans each year than HIV/AIDS, fluctuations were informally noted in previous years but never
emphysema, Parkinson’s disease, and homicide combined [14,15,16], is quantified.
a leading cause of nosocomial infections worldwide, causing over
80,000 infections and 11,285 related deaths each year in the United
States alone [17]. While invasive MRSA rates have declined in hospital- Methods and Materials
based settings in the past decade [18], a prominent global emergence of
community-associated MRSA (CA-MRSA), a strain characterized by its Collection and Filtration of Sporadic Samples
cutaneous infections in otherwise healthy individuals, has surfaced in Ear and nose samples were collected from 225 Coastal Carolina
non-clinical settings, causing skin and soft tissue infections, University volunteers over a five-year period from 2014 to 2018. Swabs
osteomyelitis, sepsis, endocarditis, toxic shock syndrome, along with were taken behind the ear and inside the nasal cavity for each volunteer.
necrotizing pneumonia [19,20,21]. CA-MRSA, a pathogen of epidemic Swab samples were then placed in 1.5 mL microcentrifuge tubes
proportions in the United States, has subsequently been non- (Carolina Biological Supply Company) containing 750 µL of phosphate
discriminatory in its selection of hosts, infecting high school, college, buffer saline (PBS Tablets, Calbiochem), and were incubated at room
and professional athletes; men who have sex with men; military temperature (25°C) for 30 minutes. Sterile filtration of PBS samples was
personnel; prison inmates; and children in day care centers [22]. performed using a 25 mm syringe filter with 0.2 µM PTFE membrane
Therefore, no group of individuals can be considered not at risk. (VWR International) attached to a 10 mL syringe with Luer-Lok Tip
Furthermore, a single clone of Staphylococcus aureus does not cause CA (BD). PBS samples were filtered into sterile 1.5 mL microcentrifuge
-MRSA; rather, global CA-MRSA infections are the result of tubes.
geographically divergent clones in which clonal replacement has been
observed in numerous studies [23-28]. This large number of increasingly Collection of Long-Term Samples
virulent and transmissible CA-MRSA clones dispersed around the world Fifteen (15) individuals from Coastal Carolina University volunteered
is a problem that is propagated by the fact that effective treatment for samples on a monthly basis from October 2017 to March 2018. Swabs
MRSA remains elusive and limited [29]. Thus, despite the recent were taken from behind the ear and inside the nasal cavity; processing
availability of new antibiotics for Staphylococcus aureus [30], new and procedures were identical to those utilized during the sporadic study.
effective treatment options need to be explored as a means to efficiently Volunteers remained anonymous throughout the study and were given
treat antibiotic-resistant S. aureus strains well into the future [12]. One numbers as a means of identification. This pilot investigation was
such naturally occurring treatment option is bacteriophage therapy, a conducted in conjunction with the sporadic study.
promising solution to the worldwide MRSA epidemic.
Amplification of Viral Particles
Staphylococcus aureus is a common bacterial strain that can be found in Amplification of viral particles was conducted using both Escherichia
the nose, pharynx, perineum, axillae, and skin of humans. Persistent coli B and Staphylococcus aureus cultures, and was performed via
colonization of S. aureus and MRSA can be observed in approximately addition of 100 uL filtered sample to a 15 mL culture tube (Thermo
30% and 1.0%, respectively, of the United States population [31,32]. Fisher) containing 3.0 mL of LB Miller broth (Sigma-Aldrich) and 200
This commonplace nature of S. aureus serves as a foundation for uL commercial Escherichia coli B (Carolina Biological Supply
studying Staphylococcus aureus and respective S. aureus bacteriophages Company). Such amplification was repeated using commerciallyin any local group in the United States. This study thus investigated the supplied Staphylococcus aureus (Carolina Biological Supply Company)
population of Coastal Carolina University (CCU), a higher educational as host.
institution situated in Conway, South Carolina. When taking into
consideration the striking ubiquitous nature of bacteriophages in Plaque Assays
conjunction to the potential S. aureus reservoir amongst the CCU Plaque assays were prepared using sterile LB Miller broth and agar
populace, Staphylococcus aureus bacteriophages were predicted to be (Agar Grade A, BD) cell culture plates. Bacterial lawns were established
prevalent on randomly sampled volunteers from CCU. In addition, on individual plates via addition of 75 µL of log-phase S. aureus liquid
Escherichia coli phage, or coliphage, populations were also investigated culture, of which was evenly distributed via a sterile spread plate
using the same samples provided by volunteers; the presence of technique. Spread plates were then incubated at 37°C for 30 minutes.
coliphages are indicative of the presence of E. coli strains, of which Five microliters (5 µL) of amplified viral sample was added to three
serve as indicators not only of fecal contamination, but temporal marked locations on a given plate, whilst 5 µL of PBS served as negative
competition to the commonly-found Staphylococcus aureus bacterial control for a fourth designated location on the plate. Amplified viral
strains expected to colonize students. Thus, coliphage populations were aliquots were dried for 10 minutes at 37°C. Plaque assays were then
simultaneously studied in conjunction with S. aureus phage populations incubated overnight at 37°C. Analysis of plaque formation, if present,
on individual student volunteers.
was conducted the following day. These plaque assay procedures were
Investigation of coliphage and S. aureus phage populations was repeated using E. coli as bacterial host.
conducted from 2014 to 2018. Over this five-year period, 225 randomly
selected volunteers from Coastal Carolina University were swabbed DNA Extraction
behind ears and inside nasal capacities. Samples were filtered and For viral capsid cleavage, 100 µL of amplified sample was placed into a
amplified. Microbial tests were conducted in order to detect lytic sterile 1.5 mL microcentrifuge tube containing 10 µL of Proteinase K
activity, while molecular techniques were used in order to confirm the (ThermoFisher). Samples were vortexed and allowed to incubate for one
presence of specific bacteriophages. The purpose of this study was to hour at 37°C. Denaturation of Proteinase K enzymes was induced by
address two questions about bacteriophages: does the Coastal Carolina placing samples in a heating block for 10 minutes at 95°C. Viral capsid
University population contain bacteriophages that are lytic to cleavage was conducted for both S. aureus and E. coli samples.
Staphylococcus aureus and, if so, can these bacteriophages be isolated
and identified based on polymerase chain reaction (PCR) techniques? Polymerase Chain Reaction
Additionally, does the CCU community contain coliphages lytic to Polymerase chain reaction was conducted in a 50 uL reaction

Journal of the South Carolina Academy of Science, [2018], 16 (1) | 30

Undergraduate Research Article
volume consisting of 25 µL of GoTaq Green Master Mix (Promega
Corporation), 21 µL of template (treated sample), and 4 uL of a
respective primer set (See Table 1) to a 0.2 mL microcentrifuge tube
(VWR International). PCR analysis was performed using a Bio-Rad
Laboratories, Inc., MJ Mini Thermal Cycler. The thermocycler program
comprised of an initial 4 minute DNA unwinding step at 95°C, followed
by 39 cycles of 30 seconds at 94°C for DNA denaturation, 1 minute at
55°C for primer annealing, and 72°C for 2 minutes for DNA extension.
The final PCR product was then held at 4°C for temporary storage. PCR
analysis was conducted for both S. aureus and E. coli phage samples.
Coliphage primer sets included CPA, CPB, and CPO; S. aureus phage
primer sets included SPA and SPB.
Gel Electrophoresis and Gel Imaging
Examination of both S. aureus and E. coli PCR products was then
conducted using a 2% agarose gel (Agarose I, VWR) in 1x Tris-acetateEDTA (TAE) buffer solution. The gel was stained with 5 µL of ethidium
bromide. Five (5 µL) of PCR product and 2 µL of 1 kb DNA ladder
(Promega Corporation) was loaded to designated wells. The agarose gel
was run for 60 minutes at 120 volts and then examined under UV light
via the Molecular Imager ChemiDoc XRS+ Imaging System from BioRad Laboratories, Inc.
Primers
Individual primers such as K1F, 933, Micro, T4, HK, Mu, N4, JK, and
Lambda that comprise coliphage primer sets CPA and CPB, as
delineated in Table 1, were extracted from the 2009 UNC Chapel
dissertation by Hee Suk Lee [33]. Primers ORF23 and ORF43 that
constitute primer set CPO were developed by Dr. Paul E. Richardson’s
lab at Coastal Carolina University. Primers such as 3A-Like, TwortLike, 11-Like, and 77-Like that comprise primer sets SPA and SPB were
derived from R. Pantůček, et al. [34]. The 4 µL individual reaction for
coliphage primer set CPA consisted of 0.2 µL HK Forward (“For”), 0.2
µL HK Reverse (“Rev”), 0.2 µL 933For, 0.2 µL 933Rev, 0.2 µL T4For,
0.2 µL T4Rev, 0.2 µL MicroFor, 0.2 µL MicroRev, 0.2 µL K1FFor, 0.2
µL K1FRev, and 2 µL of nuclease-free water (Promega Corporation).
The 4 µL individual reaction for coliphage primer set CPB consisted of
0.22 µL MuFor, 0.22 µL MuRev, 0.22 µL Lambda For, 0.22 µL Lambda
Rev, 0.22 µL JKFor, 0.22 µL JKRev, 0.22 µL N4For, 0.22 µL N4Rev,
and 2.22 µL of nuclease-free water. The 4 µL individual reaction for
coliphage primer set CPO consisted of 0.67 µL ORF23 For, 0.67 µL
ORF23 Rev, 0.67 µL ORF43 For, 0.67 µL ORF43 Rev, and 1.33 µL of
nuclease-free water. The 4 µL individual reaction for S. aureus primer
set SPA consisted of 0.5 µL 3A-Like For, 0.5 µL 3A-Like Reverse, 0.5
µL Twort Forward, 0.5 µL Twort Reverse, and 2.0 µL of nuclease-free
water. The 4 µL individual reaction for S. aureus primer set SPB
consisted of 0.5 µL 11-Like Forward, 0.5 µL 11-Like Reverse, 0.5 µL
77-Like Forward, 0.5 µL 77-Like Reverse, and 2.0 µL of nuclease-free
water.

collected from 2014 to 2018, 12.9% and 36.4% of all E. coli samples
tested positive using PCR and microbial techniques, respectively.
Positive PCR results ranged from 0.0% of all 35 samples in 2016 to
36.7% of all 60 samples collected in 2017. Of the total 82 lytic E. coli
plaque assays analyzed, only 35.4% could be characterized via
consensus sequence primers represented in Table 1.
Long-Term Project Pilot Study
Immense fluctuations in both S. aureus and E. coli phages were
observed between October 2017 and March 2018 (Figures 1-2). The
greatest number (N) of positive S. aureus phage samples were
predominantly observed in the months of October (NSE=13, NSN=14,
Figure 1; NSE=5, NSN=4, Figure 2) and November (NSE=5, NSN=6, Figure
1; NSE=1, Figure 2), after which the local S. aureus phage population
staved off to zero for both nose and ear samples while the local
coliphage population upsurged in February (NCE=2, NCN=2, Figure 1;
NCE=0, NCN=3, Figure 2) and March (NCE=5, NCN=1, Figure 1; NCE=7,
NCN=3, Figure 2).

Figure 1. Summary of positive coliphage ear (CE), coliphage nose
(CN), S. aureus phage ear (SE), and S. aureus phage nose (SN) PCR
samples from October 2017 to March 2018 in long-term pilot study.
No long-term data collected for January 2018.

Results
Sporadic Project: S. aureus phages
From 2014 to 2018, an average of 42.9% of all Staphylococcus aureus
plaque assays were observed to have indications of lytic activity (Table
Figure 2. Summary of positive coliphage ear (CE), coliphage nose
2). Positive S. aureus plaque assays ranged from 23.3% of all 30
(CN), S. aureus phage ear (SE), and S. aureus phage nose (SN)
samples collected in 2014 to 66.7% of all 60 samples collected in 2017,
plaque assays from October 2017 to March 2018 in long- term pilot
with a standard deviation of 16.1%. Of the 225 samples collected over
study. No long-term data collected for January 2018.
the designated five-year period, 21.8% and 45.3% of all S. aureus
samples tested positive using molecular-based (PCR) and microbialbased techniques, respectively. Positive PCR results ranged from 8.57%
of all 35 samples in 2016 to 32.7% of all 30 samples collected in 2014, Discussion
with a standard deviation of 10.8%. Of the total 102 lytic S. aureus
plaque assays analyzed, only 48.0% could be characterized via the The Coastal Carolina University population was found to contain
consensus sequence primers delineated in Table 1.
bacteriophages lytic to Staphylococcus aureus, as is indicated by an
average of 45.3% of all S. aureus plaque assays showing positive lytic
Sporadic Project: E. coli phages
activity (Table 2) in plague assays. Yet, of these 102 lytic S. aureus
From 2014 to 2018, an average of 36.8% of all Escherichia coli plaque assays, only 49 samples (48.0%) were identified via PCR analysis. All
assays were observed to have indications of lytic activity, as delineated 49 samples were classified as 77-Like phages; no other characterizations
in Table 3. Positive E. coli plaque assays ranged from 20.0% of all 45 such as 3A-Like, 11-Like, or Twort-Like were discerned. Such a
sporadic samples collected in 2018 to 51.7% of all 60 samples collected disparity in molecular phage identification can be attributed to the S.
in 2017, with a standard deviation of 14.4%. Of the 225 samples aureus primer sets used: primer sets SPA and SPB, as extracted from R.
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Table 1. Summary of primer sets used. Primers comprising primer sets SPA and SPB were extracted from R. Pantůček, et al.
[34]. Primers comprising primer sets CPA and CPB were derived directly from the work of Hee Suk Lee [33]. Primer set CPO
was developed by Dr. Paul E. Richardson, the principal investigator (PI) of this study.
Gene Target

PCR
Fragment
Length (bp)

Podoviridae

CKV1F, gp34

2110

Podoviridae

933Wp09, hkaG
gene

488

Primer Target Family/
Set
Organism

CPA

Hypothetical
protein

Microviridae
Myoviridae

Major head protein
(gene 23)
cII protein

Siphoviridae

1039
704
177

Myoviridae

Tail fiber gene
(MUP49)

171

Podoviridae

Hypothetical
protein

2285

Siphoviridae

Tail fiber protein

878

Siphoviridae

B gene

307

Coliphage T2/
T4

ORF 23
(Major capsid
protein)

405

CPB

CPO

Coliphage T2/
ORF 43
T4
(DNA polymerase)
3A-like phages

Tail Fibers

198
744

SPA
Twort-like
phages

Major capsid
protein

331

11-like phages

Hypothetical tail
proteins

405

77-like phages

Hypothetical tail
proteins

155

SPB

Primer Name

Primer Size
(bp)

Primer Sequences (5’ to 3’)

K1FFor

16

TGGAAGCCCGTGAGAC

K1FRev

18

GCAGCGTCAATCGCTCGG
GCAATACATCAAACGCCG

933For

18

933Rev

16

GCGAATGCCAGCGGCG

MicroFor

25

GCTGCCGTCATTGCTTATTATGTTC

MicroRev

25

GYTAYCGBMMCATYAAYTAHTCACG

T4setFor

20

GATATTTGTGGYGTTCAGCC

T4setRev

24

GTCAAATACACCAGCTTTAGAACC

HKsetFor

20

CACAGCGAGAAATTGATCGC

HKsetRev

19

CTAATCGGACTGATGTCTG

MusetFor

21

GAAAACGACTCAATCCTTGCC

MusetRev

20

TCATCAGGTCTTTTGTTGTGG

N4For

20

GCACATGCAGAATAAGGTTG

N4Rev

20

CCATTAGTAACACCATCTGC

JKsetFor

16

GYGAYCAGATGGTTCC

JKsetRev

16

CAATRTCYTCYTARTTG

LambdaFor

20

TGGGCGTACTTTATGGGGCG

LambdaRev

20

CGGACCTGCTGGGCAAAAAT

ORF23For

20

TGGCGCAGTAACTCAGATTG

ORF23Rev

20

GCACAGCTTCCATTTGTTT

ORF43For

20

CCCTGCGCCTTTCATAATAA

ORF43Rev

20

ATCGCAGGAACAGCTCCTAA

3A-like For

20

TATCAGGCGAGAATTAAGGG
CTTTGACATGACATCCGCTTGAC

3A-like Rev

23

Twort-like For

20

TGGGCTTCATTCTACGGTGA

Twort-like Rev

23

GTAATTTAATGAATCCACGAGAT

11-like For

22

ACTTATCCAGGTGGCGTTATTG

11-like Rev

23

TGTATTTAATTTCGCCGTTAGTG

77-like For

19

CGATGGACGGCTACACAGA

77-like Rev

23

TTGTTCAGAAACTTCCCAACCTG

Table 2. Sporadic project summary of S. aureus microbial (plaque assay) and molecular (PCR) results by
year. *Molecular tests were not conducted during the 2014 study year.
% of Positive
# of Positive
# of
% of Positive
S. aureus
Year
# of Samples
S. aureus
S. aureus Positive S. aureus Molecular
Microbial
Microbial Tests
Molecular Tests
Tests
Tests
2014

30

7

23.3%

N/A*

N/A*

2015

55

21

38.2%

18

32.7%

2016

35

17

48.6%

3

8.57%

2017

60

40

66.7%

18

30.0%

2018

45

17

37.8%

10

22.2%

Total

225

102

45.3%

49

21.8%

Yearly Average

45

20.4

42.9%

12.25

23.4%

Journal of the South Carolina Academy of Science, [2018], 16 (1) | 32

Undergraduate Research Article

Table 3. Sporadic project summary of E. coli microbial (plaque assay) and molecular (PCR) results by year.
*Molecular tests were not conducted during the 2014 study year.
% of Positive
E. coli Microbial
Tests

# of
E. coli Positive
Molecular
Tests

% of Positive
E. coli Molecular
Tests

Year

# of Samples

# of Positive E.
coli Microbial
Tests

2014

30

12

40.0%

N/A*

N/A*

2015

55

13

23.6%

7

12.7%

2016

35

17

48.6%

0

0.0%

2017

60

31

51.7%

22

36.7%

2018

45

9

20.0%

0

0.0%

Total

225

82

36.4%

29

12.9%

Yearly Average

45

16.4

36.8%

7.25

12.4%

Pantůček, et al., consisted of conserved genomic sequences characteristic
only of S. aureus phage types 3A, 11, 77, and Twort, of which are
representative of bacteriophage serogroups A, B, F, L, and D.
Serogroups A, B, and F comprise temperate phages that may enter a lytic
cycle in favorable environmental conditions, and thus may only prove
useful in S. aureus phages that make use of both lysogenic and lytic
cycles. This study, it must be noted, principally focused on phages lytic
to Staphylococcus aureus, albeit temperate phages were simultaneously
characterized via PCR analysis, as well, as many non-lytic S. aureus
samples were shown to be positive for lysogenic strains. Furthermore, S.
aureus primer sets derived from R. Pantůček, et al., only represent five
out of the eleven S. aureus phage serogroups [35]. Thus, the fact that
only 48.0% of all lytic S. aureus plaque assay samples could be
identified and characterized via PCR analysis may be due to utilizing
primer sets unrepresentative of every Staphylococcus aureus phage
serotype. Another speculation may be that the S. aureus phage human
reservoir has yet to be thoroughly explored, as only around 250
staphylococcal bacteriophages have ever been described in literature;
likewise, S. aureus phages that have thus far been characterized, in turn,
were determined to have high diversity and mosaicism in genomic
constitution resulting from recombination and horizontal transfer of
sequences [34]. Thus, the S. aureus phage reservoir appears to be not
only rich in the number of clandestine lytic constituents, but potentially
abundant in a diverse repository of staphylococcal phages yet to be
characterized. Exploration of novel primers may improve such molecular
phage characterization, and thus provide improved insight into the depth
of the S. aureus phage cistern and its promising utility against
Staphylococcus aureus and its antibiotic resistant variants.
As aforementioned, an average of 42.9% of all S. aureus plaque assays
had indications of lytic activity. Assuming automatic phage presence
amongst naturally-occurring S. aureus colonies in human populations,
this statistic generally coincides with the data published by the American
College of Physicians (ACP) of which, using extrapolated data,
predicted Staphylococcus aureus cultures colonize around 31.6% of
individuals in the United States [38]. This study focused on the
university population of individuals living in an environment comprised
of a stressful atmosphere and a higher population density, of which may
contribute to an inflation in the human community phage reservoir. A
more pronounced phage population, in turn, can be attributed to stressrelated immunosuppression, stress-induced susceptibility to bacterial
infections, and therefore elevated phage production and increased phage
detection rates.
Analogously, of the 82 lytic E. coli plaque assays analyzed, only 35.4%
could be identified and characterized via PCR analysis (Table 3). Such a
divergence may also be attributed to the primer sets used, as CPA, CPB,
and CPO primer sets represent somatic coliphages belonging to the
following taxonomic families: Podoviridae, Microviridae, Myoviridae,
and Siphoviridae, along with ICTV type T4, of which represents its own

group. The discrepancy in molecular identification of lytic coliphages
could therefore be associated with primer sets that appear inadequate in
representing the extremely diverse group of somatic coliphages.
A reservoir of coliphages appears to be prominent amongst the Coastal
Carolina University human population, as 36.8% of all volunteers
sampled between 2014 and 2018 were found to be positive for
coliphages (Table 3). Forty-five percent (45%) of all positive PCR
products were detected using the CPO primer set, of which includes
primers ORF 23 and ORF 43 that encode a major capsid protein and Teven DNA polymerase enzyme, respectively. Fifty-five percent (55%) of
all positive coliphage PCR products were identified via CPA and CPB
primer sets. Such discrepancy can be described in terms of the
specificity of the target genes of primer sets: the CPO primer set targets
highly conserved T-even phage consensus sequences encoding the Teven DNA polymerase and a T-even major capsid protein. Primer sets
CPA and CPB, originally derived from the work of Hee Suk Lee, were
developed for the purpose of optimizing group-specific PCR detection of
coliphage families that were predominantly found in fecal contaminated
water settings [33]. Local coliphage detection via utilization of primer
set CPO has been confirmed by Cannon, et al., [36], while coliphage
detection using CPA and CPB has been confirmed in Chapel Hill, North
Carolina, an area relatively close in distance and climate to Coastal
Carolina University [33]. Such identification of phages in diverse
locations suggests that sampled bacteriophages appear widely
distributed, as members of identified taxonomic groups using specific
primer sets CPA, CPB, and CPO have not only been found in water
sources, as suggested by Cannon, et al. [36], and Lee [33], but also
amongst the human population, as confirmed and delineated by this
study. Transportation schemes of coliphages between water sources,
fecal matter, and the human population remain unknown and
unquantified, albeit the presence of coliphages remains to be viewed as
an indicator of fecal contamination.
The immense profusion of coliphages amongst the Coastal Carolina
University population may be the result of relatively high population
density and stress-induced immunosuppression, of which may increase
susceptibility to bacterial infection and thus elevate localized phage
production. Most notably, coliphages can serve as indicator species of
fecal contamination, as aforementioned, and therefore may represent
individual hygiene level at a given moment of time, and possibly
susceptibility to bacterial colonization and thus phage proliferation.
The long-term study circumscribing bacteriophage population
fluctuations strove to quantify primordial trends observed in local S.
aureus and E. coli phage population dynamics. Staphylococcus aureus
bacteriophage numbers were observed to be greatest in number in
October of 2017, after which positive S. aureus sample numbers for both
molecular (Figure 1) and microbial (Figure 2) tests declined. No positive
PCR products were observed for coliphage samples from October 2017
to December 2017, albeit 4 positive coliphage PCR products were
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observed starting in February of 2018. In March 2018, the last month of
observation, 6 positive coliphage molecular samples were detected. A
few positive coliphage plaque assays were observed from October 2017
through December 2017, albeit a tremendous escalation in positive
samples was seen around February of 2018 (Figure 2). This small pilot
study illustrated the prospective notion that coliphage occupancy is
capable of representing temporal competition to Staphylococcus aureus
phages (and vice versa), as S. aureus phage populations appear to
decline while coliphage populations tend to escalate, as can be visualized
by both Figure 1 and Figure 2. Furthermore, this pilot study provided
insight into local phage population fluctuations, of which could also
potentially be attributed to external factors such as UV exposure,
physiological and biological stress, mechanical damage, along with the
utilization of various skin products such as acne treatments and sun
block.

Conclusion
Plaque assay results for both coliphage and S. aureus phage sporadic
studies signify that broad detection of bacteriophages appears best with
microbial techniques, albeit molecular methods remain valuable for
sensitive detection of both lytic and lysogenic phages. Results indicated
that an extensive lytic bacteriophage reservoir against Staphylococcus
aureus can be found in the general populace of Coastal Carolina
University, albeit the local S. aureus phage population remains dynamic
in nature and appears to fluctuate immensely for unknown but
speculative reasons. With the growing antibiotic resistant communityassociated MRSA threat, harvesting and exploring the utility of
bacteriophages, the natural bactericidal products crafted by billions of
years of evolution, may prove to be immensely useful to humanity as a
whole in its fight against antibiotic resistant infections.
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